USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AVANIR PHARMACEUTICALS
Address:
AVANIR PHARMACEUTICALS
11388 SORRENTO VALLEY RD, STE 200
SAN DIEGO, CA 92121 0134
Phone:
(858) 622-5215
URL:
N/A
EIN:
330314804
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,050,263.00 5
SBIR Phase II $1,008,843.00 1

Award List:

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Laura E. Pope
Abstract:
N/a

DOCOSANOL AND ACYCLOVIR FOR TREATING GENITAL HERPES

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (Provided by applicant): There is a substantial need for a safe, effective topical treatment for genital herpes simplex (HSV) disease. The proposed research aims to evaluate feasibility of continued development of docosanol as a topical treatment for… More

DOCOSANOL AND ACYCLOVIR FOR TREATING GENITAL HERPES

Award Year / Program / Phase:
2002 / SBIR / Phase II
Award Amount:
$1,008,843.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (Provided by applicant): There is a substantial need for a safe, effective topical treatment for genital herpes simplex (HSV) disease. The proposed research aims to evaluate feasibility of continued development of docosanol as a topical treatment for… More

Diverse Neutralizing Human Monoclonal Antibodies to CMV

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this proposal (Phase I and II) is to develop a human monoclonal antibody-based preparation for use in treating CMV infections or transmission. Commercial applications for human monoclonal antibodies are extensive. Phase I specific aims… More

Diverse mix of Human MoAbs to treat Anthrax exposure

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by the applicant): The long-term goal of this proposal (phase I and II) is the development of a human monoclonal antibody-based preparation for use in treating B. anthracis (anthrax) exposure or for use prophylactically. This preparation would most likely be composed of… More

Human Antibodies for Exposure/Protection from Anthrax

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$750,263.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Avanir Pharmaceuticals Inc., has developed a powerful platform for the rapid generation of high affinity fully human monoclonal antibodies that can be selected on their ability to neutralize anthrax toxin PA as exemplified by our lead candidate 8C1 (Kd 1.2… More